Name: ABCIXIMAB (ReoproR)
Classification: platelet glycoprotein IIb/IIIa receptor antagonist (human monoclonal antibody)
  • inhibits platelet aggregation
  • used with heparin and aspirin as adjunct to percutaneous transluminal coronary angioplasty
Dose: IV Direct: 
  • 0.25mg/kg over at least 1 minute given 10-60 minutes pre procedure
Administration: IV Infusion: 
9 mg / 250 ml NS
  • run at 10 ug/min for 12 hours post cardiac catheterization
  • should be administered with a 0.2 micron filter
  • requires dedicated line
Adverse Effects:
  • bleeding
  • thrombocytopenia
  • numbness or peripheral pain
  • nausea
  • hypotension
  • arrhythmias
  • nausea
  • should not be readministered to patients due to potential antibody formation with initial dose
Monitoring Therapy:
  • platelet count
  • bleeding
  • ECG
  • CCTC Protocol:
    • Must be administered by a physician.
    • Should not be infused through the injection port of the right heart catheter.
    • Must be administered as a continuous infusion via an infusion pump.

    Lynne Kelly, Pharmacist, CCTC
    Brenda Morgan, Clinical Nurse Specialist, CCTC
    Last Update: August 7, 2006

    LHSCHealth Professionals

    Last Updated March 24, 2009 | © 2007, LHSC, London Ontario Canada